Gastroenterology

Gastroenterology

Volume 148, Issue 1, January 2015, Pages 221-244.e3
Gastroenterology

AGA Section
American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

https://doi.org/10.1053/j.gastro.2014.10.038Get rights and content

Abbreviations used in this paper

ALT
alanine aminotransferase
anti-HBc
antibody to hepatitis B core antigen
anti-HBs
antibody to hepatitis B surface antigen
AST
aspartate aminotransferase
CHOP
cyclophosphamide, doxorubicin, vincristine, and prednisone
CI
confidence interval
FDA
Food and Drug Administration
GRADE
Grading of Recommendations Assessment, Development and Evaluation
HBeAg
hepatitis B e antigen
HBsAg
hepatitis B surface antigen
HBV
hepatitis B virus
HBVr
hepatitis B virus reactivation
PICO
population, intervention, comparison, and outcome
R-CHOP
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
RCT
randomized controlled trial
RR
relative risk
TACE
transarterial chemoembolization
TNF
tumor necrosis factor

Cited by (0)

This article has an accompanying continuing medical education activity on page e16. Learning Objective: Upon completion of the CME activity, successful learners will be able to describe the relative risk for the occurrence of HBV reactivation according to the type immunosuppressive drug therapy used and the serologic profile of the HBV infected individual. The learner will also be able to describe how HBV screening is essential to appropriate use of antiviral prophylaxis as a means of reducing the risk of HBV reactivation.

Reprint requests Address requests for reprints to: Chair, Clinical Practice and Quality Management Committee, AGA National Office, 4930 Del Ray Avenue, Bethesda, Maryland 20814. e-mail: [email protected]; telephone: (301) 941-2618.

Conflicts of interest The authors disclose the following: R.P.P. has served as a consultant for Gilead Sciences and Novartis. R.G. has served as a consultant for Gilead Sciences, Novartis, AbbVie, Merck, and Idenix. Y.T.F.-Y. discloses no conflicts.

View Abstract